Article Information
History
- October 5, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Eric Salazara,b,
- Paul A. Christensena,
- Edward A. Gravissa,c,
- Duc T. Nguyenc,
- Brian Castilloa,
- Jian Chena,
- Bevin Valdez Lopezd,
- Todd N. Eagara,b,
- Xin Yia,b,
- Picheng Zhaoa,
- John Rogersa,
- Ahmed Shehabeldina,
- David Josepha,
- Faisal Masude,
- Christopher Levequea,
- Randall J. Olsena,b,c,
- David W. Bernarda,b,
- Jimmy Golliharf and
- James M. Mussera,b,c,#
- aDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- bDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
- cCenter for Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute, Houston, Texas
- dAcademic Office of Clinical Trials, Houston Methodist Research Institute, Houston, Texas
- eDepartment of Anesthesiology and Critical Care, Houston Methodist Hospital, Houston, Texas
- fCCDC Army Research Laboratory-South, University of Texas at Austin, Austin, Texas
- ↵#Corresponding author: James M. Musser, MD, PhD, 6565 Fannin St., Suite B490, Houston, TX 77030, Phone: 713.441.5890, Fax: 713.441.3886, Email: jmmusser{at}houstonmethodist.org
Posted October 05, 2020.
Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality
